A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs

References

• Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147–239. Epub 2013 Jun 5. No abstract available
   PubMed Web of Science ®Google Scholar
• 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;DOI:10.1002/ejhf.592
   Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133(4):447–454.
   PubMed Web of Science ®Google Scholar
• Castelli G, Fornaro A, Ciaccheri M, et al. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. Circ Heart Fail. 2013;6(5):913–921.
   PubMed Web of Science ®Google Scholar
• Jones NR, Richard Hobbs FD, Taylor CJ. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. BJGP Open. 2017;1(3): BJGP-2016-0021. DOI:10.3399/bjgpopen17X101013.
   Google Scholar
• Shah SR, Luu SW, Calestino M, et al. Management of atrial fibrillation-flutter: uptodate guideline paper on the current evidence. J Community Hosp Intern Med Perspect. 2018 Oct 15;8(5):269–275. eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–619.
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Triposkiadis F, Butler J. Metformin use in patients with diabetes mellitus and heart failure: friend or foe? J Card Fail. 2010;16(3):207–210.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care. 2005;28(7):1680–1689.
   PubMed Web of Science ®Google Scholar
• Shah SR, Moosa PG, Fatima M, et al. Atrial fibrillation and heart failure – results of the CASTLE-AF trial. J Community Hosp Intern Med Perspect. 2018 Aug 23;8(4):208–210. eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Andersson C, Olesen JB, Hansen PR, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53(12):2546–2553.
   PubMed Web of Science ®Google Scholar
• Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395–402.
   PubMed Web of Science ®Google Scholar
• Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–228.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) group intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.
   PubMed Web of Science ®Google Scholar
• Shah SR, Alweis R. Acute coronary artery dissection: a review of the literature and current evidence. Cardiol Rev. 2017 Dec 12. doi: 10.1097/CRD.0000000000000186.
   Web of Science ®Google Scholar
• McAlister FA, Eurich DT, Majumdar SR, et al. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008;10(7):703–708.
   PubMed Web of Science ®Google Scholar
• Vaccaro O, Masulli M, Bonora E, et al. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care. 2012;35(12):e82.
   PubMed Web of Science ®Google Scholar
• Shah SR, Winchester DE. The impact of chronic kidney disease on medication choice and pharmacologic management in patients with heart failure. Expert Rev Clin Pharmacol. 2018 Jun;11(6):571–579. Epub 2018 Jun 4.
   PubMed Web of Science ®Google Scholar
• Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus Glimepiride in type 2 diabetes (CAROLINA(R)). Diab Vasc Dis Res. 2015;12(3):164–174.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254–2261.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–2135.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Shah SR, Fatima K, Ansari M. Recovery of myofilament function through reactivation of glycogen synthase kinase 3β (GSK-3β): mechanism for cardiac resynchronization therapy. J Interv Card Electrophysiol. 2014 Dec;41(3):193–194.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Abdullah SM, See R, et al. Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. Eur Heart J. 2010;31(18):2262–2270.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2015;132(15):e121–e122.
   PubMed Web of Science ®Google Scholar
• Savarese G, D’Amore C, Federici M, et al. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked coTransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int J Cardiol. 2016;220:595–601.
   PubMed Web of Science ®Google Scholar
• Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, et al. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol. 2016;211:88–95.
   PubMed Web of Science ®Google Scholar
• Luconi M, Cantini G, Ceriello A, et al. Perspectives on cardiovascular effects of incretin-based drugs: from bedside to bench, return trip. Int J Cardiol. 2017;241:302–310.
   PubMed Web of Science ®Google Scholar
• Wsd SJ, Afd G-M, Kraemer-Aguiar LG. Dipeptidyl peptidase 4: a new link between diabetes mellitus and atherosclerosis? Biomed Res Int. 2015;2015:10.
   Google Scholar
• Shah SR, Uddin MF, Lateef N, et al. Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial. J Community Hosp Intern Med Perspect. 2017 Jul 13;7(3): 199–200. eCollection 2017 Jul.
   PubMed Web of Science ®Google Scholar
• Shah SR, Fatima M, Dharani AM, et al. Bioresorbable vascular scaffold versus metallic stent in percutaneous coronary intervention: results of the AIDA trial. J Community Hosp Intern Med Perspect. 2017 Oct 18;7(5):307–308. eCollection 2017.
   PubMed Web of Science ®Google Scholar
• Balakumar P, Dhanaraj SA. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Cell Signal. 2013;25(9):1799–1803.
   PubMed Web of Science ®Google Scholar
• Solini A, Rossi C, Duranti E, et al. Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase. Vascul Pharmacol. 2015;76:62–71.
   PubMed Web of Science ®Google Scholar
• Keller AC, Knaub LA, Miller MW, et al. Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki rat. J Cardiovasc Pharmacol. 2014;65(2):137–147.
   Web of Science ®Google Scholar
• Mason RP, Jacob RF, Kubant R, et al. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol. 2012;60(5):467–473.
   PubMed Web of Science ®Google Scholar
• Shah SR, Alweis R, Shah SA, et al. Effects of colchicine on pericardial diseases: a review of the literature and current evidence. J Community Hosp Intern Med Perspect. 2016 Jul 6;6(3):31957. eCollection 2016. Review.
   PubMed Web of Science ®Google Scholar
• Shah SR, Khan MS, Alam MT, et al. End stage renal disease: seroprevalence of hepatitises B and C along with associated aetiology and risk factors in children. J Trop Med. 2015;2015:936094. Epub 2015 Aug 5. PMID: 26346273.
   PubMed Web of Science ®Google Scholar
• Katsnelson LB, Sulman T, Solovyova O, et al. Role of myocardial viscoelasticity in disturbances of electrical and mechanical activity in calcium overloaded cardiomyocytes: mathematical modeling. J Theor Biol. 2011;272:83–95.
   PubMed Web of Science ®Google Scholar
• Tang S-T, Su H, Zhang Q, et al. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-B/IB system through the activation of AMP-activated protein kinase. Int J Mol Med. 2016;37(6):1558–1566.
   PubMed Web of Science ®Google Scholar
• Connelly KA, Zhang Y, Advani A, et al. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther. 2013;31(5):259–267.
   PubMed Web of Science ®Google Scholar
• Lee T-M, Chen W-T, Chang N-C. Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats. Biosci Rep. 2016;36:2.
   Web of Science ®Google Scholar
• Lee T-M, Chen W-T, Chang N-C. Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase a-dependent pathway in infarcted hearts. Circ J. 2015;79(11):2461–2470.
   PubMed Web of Science ®Google Scholar
• Lee T-I, Kao Y-H, Chen Y-C, et al. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes. Int J Cardiol. 2013;168(6):5390–5395.
   PubMed Web of Science ®Google Scholar
• Esposito G, Cappetta D, Russo R, et al. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. Br J Pharmacol. 2017;174:4070–4086.
   PubMed Web of Science ®Google Scholar
• Alam MA, Hasan Chowdhury MR, Jain P, et al. DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats. Diabetol Metab Syndr. 2015;7( 1, article no. 95). DOI:10.1186/s13098-015-0095-3.
   PubMed Web of Science ®Google Scholar
• Shah SR, Park K. Long QT syndrome: a comprehensive review of the literature and current evidence. Curr Probl Cardiol. 2018 May 10. pii: S0146-2806(18)30051-3. DOI:10.1016/j.cpcardiol.2018.04.002.
   Google Scholar
• Aoyama M, Kawase H, Bando YK, et al. Dipeptidyl-peptidase-4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/Ras-related protein 1 axis. Circulation. 2016;9:1.
   Web of Science ®Google Scholar
• Akita K, Isoda K, Shimada K, et al. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice. J Am Heart Assoc. 2015;4:3.
   Web of Science ®Google Scholar
• Kato S, Fukui K, Kirigaya H, et al. Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease. Int J Cardiol. 2016;223:770–775.
   PubMed Web of Science ®Google Scholar
• Yin M, Hhw S, Meissner M, et al. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol. 2011;10( article no. 85). DOI:10.1186/1475-2840-10-85.
   PubMed Web of Science ®Google Scholar
• Chinda K, Sanit J, Chattipakorn S, et al. Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart. Diabetes Vasc Dis Res. 2014;11(2):75–83.
   PubMed Web of Science ®Google Scholar
• Miyoshi T, Nakamura K, Yoshida M, et al. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc Diabetol. 2014;13( 1, article 43). DOI:10.1186/1475-2840-13-43.
   Web of Science ®Google Scholar
• Ishii M, Shibata R, Kondo K, et al. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism. J Biol Chem. 2014;289(39):27235–27245.
   PubMed Web of Science ®Google Scholar
• Apaijai N, Pintana H, Chattipakorn SC, et al. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. Br J Pharmacol. 2013;169(5):1048–1057.
   PubMed Web of Science ®Google Scholar
• Aroor AR, Sowers JR, Bender SB, et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male zucker obese rats. Endocrinology. 2013;154(7):2501–2513.
   PubMed Web of Science ®Google Scholar
• Vellecco V, Mitidieri E, Gargiulo A, et al. Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway. Diabetes Obesity Metab. 2016;18(12):1236–1243.
   PubMed Web of Science ®Google Scholar
• Wang X-W, Zhang F-X, Yang F, et al. Effects of linagliptin and liraglutide on glucose-and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro. Acta Pharmacol Sin. 2016;37(10):1349–1358.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marx N, Neubacher D, et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Frandsen KB, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–508.
   PubMed Web of Science ®Google Scholar
• Jorsal A The effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes mellitus (LIVE) study. Presented at the ESC Heart Failure Congress 2016, May 24, Florence Italy
   Google Scholar
• Berkelaar M, Eekhoff EM, Simonis-Bik AM, et al. Effects of induced hyperinsulinaemia with and without hyperglycaemia on measures of cardiac vagal control. Diabetologia. 2013;56(6):1436–1443.
   PubMed Web of Science ®Google Scholar
• Valensi P, Chiheb S, Fysekidis M. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia. 2013;56(6):1196–1200.
   PubMed Web of Science ®Google Scholar
• Kumarathurai P, Anholm C, Larsen BS, et al. Effects of Liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study. Diabetes Care. 2017;40(1):117–124.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab. 2017;19(7):926–935.
   PubMed Web of Science ®Google Scholar
• Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180–1193.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28.
   PubMed Web of Science ®Google Scholar
• Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(9):691–700.
   PubMed Web of Science ®Google Scholar
• Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119–126.
   PubMed Web of Science ®Google Scholar
• Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38(6):1299–1313.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597.
   PubMed Web of Science ®Google Scholar
• Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016;89(3):524–526.
   PubMed Web of Science ®Google Scholar
• Sattar N, McLaren J, Kristensen SL, et al. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333–1339.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39(7):1108–1114.
   PubMed Web of Science ®Google Scholar
• Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37.
   PubMed Web of Science ®Google Scholar